ValuEngine cut shares of AstraZeneca (NYSE:AZN) from a buy rating to a hold rating in a research note released on Friday morning.
Several other research analysts have also recently weighed in on the stock. Jefferies Financial Group cut shares of AstraZeneca from a buy rating to a hold rating in a report on Thursday, August 16th. Zacks Investment Research raised shares of AstraZeneca from a sell rating to a hold rating in a report on Monday, July 16th. Morningstar reaffirmed a hold rating on shares of AstraZeneca in a report on Tuesday, June 12th. Finally, BMO Capital Markets reaffirmed a buy rating and issued a $41.00 price target on shares of AstraZeneca in a report on Friday, May 25th. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. AstraZeneca presently has an average rating of Hold and an average target price of $38.94.
Shares of AstraZeneca stock traded up $0.11 during trading on Friday, hitting $37.18. The stock had a trading volume of 2,167,175 shares, compared to its average volume of 3,887,245. The stock has a market cap of $93.89 billion, a P/E ratio of 8.69, a PEG ratio of 2.00 and a beta of 0.60. AstraZeneca has a 12 month low of $31.71 and a 12 month high of $39.76. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.54 and a current ratio of 0.72.
AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, July 26th. The company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.38. The firm had revenue of $5.16 billion for the quarter, compared to analysts’ expectations of $5.09 billion. AstraZeneca had a net margin of 11.98% and a return on equity of 29.89%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.87 earnings per share. sell-side analysts predict that AstraZeneca will post 1.68 earnings per share for the current year.
The company also recently announced a semiannual dividend, which will be paid on Monday, September 10th. Investors of record on Friday, August 10th will be paid a $0.45 dividend. The ex-dividend date of this dividend is Thursday, August 9th. This represents a yield of 2.35%. AstraZeneca’s dividend payout ratio is presently 20.56%.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Green Square Capital LLC increased its stake in AstraZeneca by 12.3% in the second quarter. Green Square Capital LLC now owns 14,233 shares of the company’s stock valued at $500,000 after acquiring an additional 1,558 shares during the last quarter. WealthPLAN Partners LLC increased its stake in AstraZeneca by 46.9% in the second quarter. WealthPLAN Partners LLC now owns 55,490 shares of the company’s stock valued at $1,949,000 after acquiring an additional 17,709 shares during the last quarter. Argent Trust Co bought a new position in AstraZeneca in the second quarter valued at $536,000. HPM Partners LLC increased its stake in AstraZeneca by 50.2% in the second quarter. HPM Partners LLC now owns 34,813 shares of the company’s stock valued at $1,222,000 after acquiring an additional 11,629 shares during the last quarter. Finally, Cozad Asset Management Inc. bought a new position in AstraZeneca in the second quarter valued at $434,000. 15.98% of the stock is currently owned by institutional investors and hedge funds.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.